GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » Gross Profit

Theralase Technologies (TSXV:TLT) Gross Profit : C$0.55 Mil (TTM As of Dec. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies Gross Profit?

Theralase Technologies's gross profit for the three months ended in Dec. 2024 was C$0.26 Mil. Theralase Technologies's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was C$0.55 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Theralase Technologies's gross profit for the three months ended in Dec. 2024 was C$0.26 Mil. Theralase Technologies's Revenue for the three months ended in Dec. 2024 was C$0.41 Mil. Therefore, Theralase Technologies's Gross Margin % for the quarter that ended in Dec. 2024 was 64.15%.

Theralase Technologies had a gross margin of 64.15% for the quarter that ended in Dec. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Theralase Technologies was 67.66%. The lowest was 6.33%. And the median was 54.15%.


Theralase Technologies Gross Profit Historical Data

The historical data trend for Theralase Technologies's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies Gross Profit Chart

Theralase Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.31 0.63 0.56 0.55

Theralase Technologies Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.06 0.03 0.20 0.26

Competitive Comparison of Theralase Technologies's Gross Profit

For the Medical Devices subindustry, Theralase Technologies's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralase Technologies's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Gross Profit distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's Gross Profit falls into.


;
;

Theralase Technologies Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Theralase Technologies's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=1.033 - 0.479
=0.55

Theralase Technologies's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=0.41 - 0.147
=0.26

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.55 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Theralase Technologies's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.26 / 0.41
=64.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Theralase Technologies  (TSXV:TLT) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Theralase Technologies had a gross margin of 64.15% for the quarter that ended in Dec. 2024 => Durable competitive advantage


Theralase Technologies Gross Profit Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Theralase Technologies Business Description

Traded in Other Exchanges
Address
41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
Executives
Matthew Thomas Perraton Director
Roger John Dumoulin-white 10% Security Holder, Director, Senior Officer
Kristina Maria Hachey Senior Officer
Arkady Mandel Senior Officer
Guy John Anderson Director
Shawn Shirazi Senior Officer

Theralase Technologies Headlines

From GuruFocus

Top 5 4th Quarter Trades of VANTAGEPOINT INVESTMENT ADVISERS LLC

By GuruFocus Research GuruFocus Editor 01-24-2023

Top 5 2nd Quarter Trades of K.J. Harrison & Partners Inc

By GuruFocus Research GuruFocus Editor 07-27-2022

Louis Moore Bacon Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 11-14-2022

Top 5 4th Quarter Trades of VANTAGEPOINT INVESTMENT ADVISERS LLC

By GuruFocus Research GuruFocus Editor 01-21-2023

Strong Tower Advisory Services Buys 2, Sells 3 in 4th Quarter

By GuruFocus Research GuruFocus Editor 01-21-2023

Top 5 3rd Quarter Trades of Eqis Capital Management, Inc.

By GuruFocus Research GuruFocus Editor 10-24-2022

Top 5 4th Quarter Trades of ONE PLUS ONE WEALTH MANAGEMENT, LLC

By GuruFocus Research GuruFocus Editor 01-19-2023

Rafferty Asset Management, LLC's Top 5 Buys of the 4th Quarter

By GuruFocus Research GuruFocus Editor 02-15-2023

Top 5 2nd Quarter Trades of Pinnacle Wealth Management, LLC

By GuruFocus Research GuruFocus Editor 07-29-2022